Lawrence Township-based Adare Pharmaceuticals on Monday said it acquired pharmaceutical technology company Orbis Biosciences Inc. of Lenexa, Kan. for an undisclosed amount.
The acquisition of Orbis will enhance Adare’s Pharmaceutical Technologies business, which develops and manufactures products for global pharmaceutical, animal health and over-the-counter (OTC) markets. The acquisition was finalized on April 30, 2020.
“Orbis’s customized technologies are an excellent complement to our contract development and manufacturing organization (CDMO) business which is currently focused on oral dosage forms for pharmaceutical and OTC medicines,” said John Fraher, chief executive officer of Adare Pharmaceuticals. “In particular, their platforms create drug particles that can be dosed in oral liquid, injectable, and otic dosage forms. These will broaden our product development offerings and ultimately, advance the growth of our CDMO business, further strengthening our leadership in taste-masking and controlled-release technologies.”
Orbis provides enhanced technologies in a scaled, single-step manufacturing process. Its Precision Particle Fabrication technology is the only technology currently on the market that can produce uniform particles in size ranges suitable for use in injectable, otic and oral dosage forms. The platform technology is flexible and customizable to accommodate a broad range of active ingredients, including small molecules, peptides and proteins. Orbis’s proprietary technology includes three platforms: Optimμm for oral delivery; Stratμm TM for injectable delivery; and Unisun for otic delivery.